IOVA · Iovance Biotherapeutics, Inc. · Webcasts, Transcripts & Audio
$7.76
+0.13 (+1.70%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$3.59B
Shares
462.66M
Volume · Nov 13
11.68M
Avg daily vol (3M)
16.1M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Iovance Biotherapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Iovance Biotherapeutics, Inc. (IOVA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript
Confident tone
Lung cancer clinical development
Revenue guidance and financial outlook
Sarcoma and frontline melanoma expansion
Revenue
$121.47M
▲ 80.1% YoY Diluted EPS
$-0.05
Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Iovance Biotherapeutics, Inc. (IOVA) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript
Confident tone
Demand and sales momentum for AMPAG/AMTAGV
Lung 202 trial enrollment and durability
Forward guidance update
Revenue
$99.31M
▲ 65.7% YoY Diluted EPS
$-0.11
Gross margin
56.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Iovance Biotherapeutics, Inc. (IOVA) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript
Confident tone
Amtagvi (lifileucil) commercial growth
In-house manufacturing (ICPC)
Pipeline expansion across solid tumors
Revenue
$71.43M
▲ 44.8% YoY Diluted EPS
$-0.19
Gross margin
40.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Iovance Biotherapeutics, Inc. (IOVA) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript
Confident tone
Manufacturing and operations
Cash runway and financial discipline
Gross margin improvement
Revenue
$86.77M*
▲ 17.7% YoY Gross margin
50.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript
Confident tone
Lung Cancer Pipeline (LUN202)
Manufacturing Centralization and Margin Improvement
Community and Academic ATC Expansion
Revenue
$67.45M
▲ 15.2% YoY Diluted EPS
$-0.25
Gross margin
43.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript
Positive tone
Revenue guidance and growth
Manufacturing improvements
Proleukin (ProLucan) sales
Revenue
$59.95M
▲ 92.7% YoY Diluted EPS
$-0.33
Gross margin
18.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript
Positive tone
Amtagvi U.S. commercial launch
Proleukin sales dynamics
Q1 revenue shortfall and revised guidance
Revenue
$49.32M
▲ 6798.5% YoY Diluted EPS
$-0.36
Gross margin
13.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Confident tone
Amtagvi commercial launch and uptake
Manufacturing capacity and supply
Pipeline expansion - frontline melanoma and NSCLC
Revenue
$73.69M*
Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
Confident tone
Amtagvi commercial launch and revenue
Manufacturing capacity and turnaround
Gross margin outlook
Revenue
$58.55M
▲ 12385.1% YoY Diluted EPS
$-0.28
Gross margin
46.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Iovance Biotherapeutics, Inc. (IOVA) Q2 2024 Earnings Call Transcript
Confident tone
Amtagvi U.S. Commercial Launch
Proleukin Sales and Revenue Mix
Pipeline and Label Expansion
Revenue
$31.11M
▲ 12969.7% YoY Diluted EPS
$-0.34
Gross margin
-0.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript
Confident tone
Amtagvi U.S. Commercial Launch
Commercial Manufacturing Capacity
ATC Network Expansion
Revenue
$715,000
Diluted EPS
$-0.42
Gross margin
-915.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Iovance Biotherapeutics, Inc. (IOVA) Q4 2023 Earnings Call Transcript
Confident tone
AMTAGVI U.S. Launch
Manufacturing Capacity
Financial Position
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Iovance Biotherapeutics, Inc. (IOVA) Q3 2023 Earnings Call Transcript
Revenue
$469,000
Diluted EPS
$-0.46
Gross margin
-825.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Iovance Biotherapeutics, Inc. (IOVA) Q2 2023 Earnings Call Transcript
Revenue
$238,000
Diluted EPS
$-0.47
Gross margin
-761.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Iovance Biotherapeutics, Inc. (IOVA) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Iovance Biotherapeutics, Inc. (IOVA) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Iovance Biotherapeutics, Inc. (IOVA) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Iovance Biotherapeutics, Inc. (IOVA) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Iovance Biotherapeutics, Inc. (IOVA) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Iovance Biotherapeutics, Inc. (IOVA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Iovance Biotherapeutics, Inc. (IOVA) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Iovance Biotherapeutics, Inc. (IOVA) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Iovance Biotherapeutics, Inc. (IOVA) Q1 2021 Earnings Call Transcript
Diluted EPS
$-0.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Iovance Biotherapeutics, Inc. (IOVA) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Iovance Biotherapeutics, Inc. (IOVA) Q3 2020 Earnings Call Transcript
Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Iovance Biotherapeutics, Inc. (IOVA) Q2 2020 Earnings Call Transcript
Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 webcasts
Key facts
CIK
1425205
CUSIP
462260100
13F (30d)
258 filings
237 filers
Visit website
Investor relations